Condition: Coronary Arterial Disease (CAD) · Percutaneous Coronary Intervention (PCI) · Sponsor: University of Florida
The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.
This description comes directly from the study's public registry record.
Luis Ortega-Paz, MD, PhD · 904-244 2060 · Luis.Ortega@jax.ufl.edu
Andrea Burton, MPH, CCRP · 904-244-5617 · Andrea.Burton@jax.ufl.edu
Always discuss trial participation with your own doctor first.
| University of Florida Health | Jacksonville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07025148